Swiss National Bank - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 4 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Swiss National Bank ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$5,548,994
-21.3%
155,652
+1.8%
0.00%
-20.0%
Q2 2023$7,051,063
+22.3%
152,852
+6.3%
0.01%
+25.0%
Q1 2023$5,764,455
-22.6%
143,752
-10.5%
0.00%
-20.0%
Q4 2022$7,443,007
+14.1%
160,652
+2.0%
0.01%0.0%
Q3 2022$6,524,000
-29.6%
157,552
+1.5%
0.01%
-16.7%
Q2 2022$9,262,000
-16.7%
155,252
+1.4%
0.01%0.0%
Q1 2022$11,122,000
-6.8%
153,152
+8.0%
0.01%
-14.3%
Q4 2021$11,928,000
-6.6%
141,852
+0.1%
0.01%
-12.5%
Q3 2021$12,776,000
-4.4%
141,652
+1.1%
0.01%0.0%
Q2 2021$13,363,000
-18.2%
140,152
-2.4%
0.01%
-27.3%
Q1 2021$16,345,000
-9.3%
143,552
+10.3%
0.01%
-15.4%
Q4 2020$18,017,000
+70.4%
130,152
+1.2%
0.01%
+62.5%
Q3 2020$10,574,000
+10.1%
128,652
+4.8%
0.01%0.0%
Q2 2020$9,602,000
+103.0%
122,752
+15.3%
0.01%
+60.0%
Q1 2020$4,730,000
+5.6%
106,452
+1.5%
0.01%0.0%
Q4 2019$4,478,000
+1.8%
104,852
+1.9%
0.01%0.0%
Q3 2019$4,400,000
-30.5%
102,852
+3.2%
0.01%
-28.6%
Q2 2019$6,328,000
-7.1%
99,652
+1.4%
0.01%0.0%
Q1 2019$6,815,000
+86.0%
98,252
+16.6%
0.01%
+40.0%
Q4 2018$3,663,000
-41.5%
84,252
+2.7%
0.01%
-28.6%
Q3 2018$6,264,000
-0.7%
82,0520.0%0.01%0.0%
Q2 2018$6,307,000
+59.3%
82,052
+5.7%
0.01%
+40.0%
Q1 2018$3,959,000
+22.0%
77,652
+11.0%
0.01%
+25.0%
Q4 2017$3,244,000
-9.4%
69,952
+4.0%
0.00%0.0%
Q3 2017$3,582,000
-12.7%
67,252
+1.8%
0.00%
-20.0%
Q2 2017$4,102,000
-5.4%
66,052
+3.3%
0.01%0.0%
Q1 2017$4,335,000
+0.2%
63,952
+3.9%
0.01%
-28.6%
Q4 2016$4,328,000
+1.6%
61,552
+2.5%
0.01%0.0%
Q3 2016$4,260,000
+44.3%
60,052
-0.5%
0.01%
+40.0%
Q2 2016$2,952,000
+9.2%
60,352
+36.3%
0.01%0.0%
Q1 2016$2,704,000
-31.8%
44,267
+25.2%
0.01%
-50.0%
Q4 2015$3,967,000
+18.1%
35,367
+1.4%
0.01%
+11.1%
Q3 2015$3,358,000
+29.1%
34,867
+37.3%
0.01%
+28.6%
Q2 2015$2,601,000
+64.9%
25,4000.0%0.01%
+75.0%
Q1 2015$1,577,000
+87.3%
25,400
+32.3%
0.00%
+33.3%
Q4 2014$842,000
+135.9%
19,200
+204.8%
0.00%
+200.0%
Q3 2014$357,000
+26.1%
6,3000.0%0.00%0.0%
Q2 2014$283,0006,3000.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2023
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 727,426$25,932,7374.72%
RTW INVESTMENTS, LP 5,405,089$192,691,4234.07%
First Light Asset Management, LLC 1,125,032$40,107,3913.81%
CHI Advisors LLC 215,000$7,664,7503.04%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 250,052$8,914,3543.00%
SPHERA FUNDS MANAGEMENT LTD. 259,135$9,238,1631.68%
Rock Springs Capital Management LP 1,476,441$52,635,1221.41%
SUVRETTA CAPITAL MANAGEMENT, LLC 679,459$24,222,7131.31%
Privium Fund Management B.V. 115,241$4,108,3411.22%
SECTOR GAMMA AS 115,166$4,105,6681.05%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders